With $45M in Funding, Startup Voyager Therapeutics Aims to Develop Expressed RNAi CNS Drugs | GenomeWeb

Venture capital firm Third Rock Ventures last week announced that it has put up $45 million to form a new company called Voyager Therapeutics to develop adeno-associated viral vector-enabled treatments for central nervous system disorders.

Although the company's lead program is a gene-replacement therapy for Parkinson's disease, Voyager has also set its sights on using its AAV technology to develop expressed RNAi drugs — an effort that includes a preclinical program in amyotrophic lateral sclerosis, according to a company executive.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.